R&D JP Morgan 2024 – Graham Heap Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.
News Apollo, Nimbus lead bumper week for biotech financings This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p